Strategy, commercial growth and regulatory leadership for science-led businesses

Hibernating biology. Accelerating commercial growth.

How fractional commercial leadership supported Atelerix as it evolved from market seeding towards a more strategic, value-led approach to growth 

Technology: Hydrogel preservation of living biological materials
Support: Fractional commercial leadership, sales mentoring and commercial strategy
Engagement: Three months
Headline result: Monthly revenue doubled during the engagement

The Client: Atelerix

Atelerix is not a conventional biotechnology company—and that is entirely deliberate.

Its patented alginate hydrogel technology places living biological materials into a temporary, protected state—rather like hedgehogs during hibernation. This allows cells, tissues, blood products, viruses and vectors to be stored or transported at ambient or controlled temperatures without conventional freezing. Depending on the biological material and application, samples can remain stable for up to 21 days before being recovered using a simple release buffer.

The non-toxic hydrogel is assembled from components manufactured to GMP standards and has been used successfully within clinical trial sample workflows.

The technology provides a practical bridge between sample collection, short-term storage, transport and scientific use. By reducing the need for freezing, dry ice and complex cold-chain logistics, it can make high-quality living biology easier to preserve and transport—including in regions where dependable cold-chain infrastructure is costly or limited.

Atelerix’s distinctive hedgehog branding reflects both the science and the company’s personality. It was created to attract scientists willing to question established methods and explore something new. The approach may be a little Marmite, but that is part of its strength: disruptive technology must first be noticed before it can be understood and adopted.

That personality carries through into the company’s collaborative culture. Even external team members receive their own hedgehog avatar—Sonia included—a small but telling example of the care CEO Alastair Carrington and founder and Chief Scientific Officer Steve Swioklo take in welcoming people into the team.

The Challenge

Atelerix had strong technology, a credible scientific team and an established sales pipeline. Its commercial function brought together three exceptional scientists with academic experience directly relevant to cell biology and the technology’s applications.

The opportunity was to help the team extract greater value from those foundations.

As CEO, Alastair brought considerable commercial expertise and remained closely involved in business development. However, leading a growing company limited the time available for the consistent, hands-on coaching and commercial challenge he wanted the team to receive.

Atelerix therefore needed experienced, flexible support that could:

  • build on the commercial capability and confidence of its scientifically trained team;
  • sharpen opportunity qualification and prioritisation;
  • strengthen value communication, pricing discipline and objection handling;
  • focus effort on the opportunities most likely to progress;
  • support distributor discussions; and
  • provide additional day-to-day commercial leadership without immediately adding another permanent management layer.

Protecting the company’s culture mattered just as much as improving its processes. Any adviser needed to challenge and develop the team while respecting its scientific expertise and preserving the close-knit culture of collaboration, care and genuine fun that Alastair and Steve had deliberately created.

The approach

Sonia joined Atelerix as a fractional commercial adviser, working closely with Alastair, Steve and the commercial team remotely and on site. Her involvement extended beyond formal commercial support: she collaborated with colleagues across the wider business and became a trusted part of the Atelerix team.

Atelerix already had an established rhythm of weekly sales meetings. Sonia built on this foundation by giving each discussion a sharper commercial focus. Monday meetings concentrated on the opportunities that could realistically be secured and invoiced that week, while Friday meetings examined whether earlier-stage opportunities had meaningfully progressed.

The team also identified barriers, agreed the next action and considered whether anyone across the wider business could help remove a barrier or move the opportunity forward. At both meetings, the team considered:

  • the customer’s underlying scientific and commercial need;
  • the technology’s impact compared with the customer’s current workflow, and whether it offered a sufficiently significant benefit to justify change;
  • the evidence that an opportunity remained active;
  • the decision-makers and stakeholders involved;
  • the barriers preventing progression;
  • the next meaningful customer commitment; and
  • whether the likely value justified further investment of the team’s time.

This helped the team focus more deliberately on credible later-stage opportunities while maintaining the thoughtful, scientifically led customer engagement for which Atelerix was already known.

Sonia also delivered tailored mentoring and practical training for the sales-focused colleagues in value communication, pricing, concessions and objection handling. Product samples, discounts and other concessions were linked to a defined purpose—such as enabling technical evaluation, progressing a qualified opportunity or securing an appropriate customer commitment—helping the team protect the product’s value while continuing to reassure first-time users.

Finding the commercial sweet spot

Pipeline and customer analysis showed that many opportunities reflected the technology’s early market-development stage and were linked to individual project requirements. The strongest potential for predictable repeat revenue lay with laboratories running recurring in-house experiments, where the product could become part of a routine workflow.

The team translated this insight into clearer “sweet spot” customer profiles and a repeatable test-and-learn approach:

  1. Define the target-customer hypothesis and commercial objective.
  2. Run focused outreach using tailored positioning and messaging.
  3. Assess engagement against agreed indicators.
  4. Capture what was learned about the customer, need and proposition.
  5. Refine the targeting and apply the learning to the next campaign.

This created a more systematic way to identify attractive customer segments and improve future business development activity.

Alongside the team development, Sonia provided senior commercial analysis and recommendations for consideration by the CEO and Board. She also worked with Atelerix’s technical sales specialist to develop distributor terms for a specific commercial opportunity.

The results

Monthly revenue doubled during the three-month engagement.

Alongside this growth, the engagement supported:

  • greater focus on credible later-stage opportunities;
  • more rigorous qualification based on evidence and customer commitment;
  • clearer principles for product sampling, pricing, discounts and concessions;
  • stronger confidence in communicating and defending the product’s value;
  • customer profiles centred on routine and repeat product use;
  • targeted campaigns using a repeatable test-and-learn methodology;
  • distributor terms supporting a specific opportunity; and
  • tailored mentoring and commercial development for the sales-focused colleagues.

The CEO and Board received a strategic commercial pack setting out observations, recommendations and future considerations. The stronger working practices and commercial discipline developed during the engagement were designed to remain with the team and continue evolving over time.

Lasting impact

The engagement supported Atelerix’s evolution from broad market seeding towards a more strategic, value-led commercial approach. The team strengthened how it assessed opportunity maturity, communicated the value of the technology and identified the wider engagement required to support adoption.

The CEO and CSO also gained additional commercial capacity, analysis and challenge to complement their existing leadership and Board activities.

Just as importantly, the work was delivered without losing what made the company distinctive: scientific credibility, genuine collaboration and a willingness to do things differently.

When Sonia subsequently left to take up a full-time leadership opportunity, Atelerix wanted the support to continue and appointed another consultant to continue the commercial coaching and structured approach she had helped develop within the existing weekly meeting cadence.

"Sonia has given me faith back in using consultants.
Alastair Carrington, 
CEO, Atelerix

Facing a similar commercial challenge?

If your science-led business needs clearer commercial strategy, sharper focus, stronger opportunity qualification or experienced commercial leadership without an immediate full-time appointment, let’s talk.

Interested in Atelerix’s technology?

To explore whether Atelerix’s technology could support the short-term preservation or transport of your cells, tissues or other sensitive biological materials, contact the team at sales@atelerix.co.uk.

Information icon

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.